Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

Abroad (travel likely)RecruitingPHASE3

Conditions

Thyroid Associated Ophthalmopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Faculty of Medicine Siriraj Hospital Mahidol University, Bangkok Noi, Thailand
Contact: Study coordinator (Janjira Petsuksiri, M.D.) · janjira.pet@mahidol.ac.th · 66919966662
Contact: Study coordinator (Wajana Thaweerat, M.D.) · wajana.thaweerat@gmail.com · 66941499212

Study leads

Janjira Petsuksiri, M.D.
Principal Investigator
Mahidol University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Thyroid Eye Disease · Graves Orbitopathy · Endocrine System Diseases

Abroad (travel likely)RecruitingPHASE2, PHASE3

Miami, United States · Morgantown, United States

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

Graves Ophthalmopathy · Thyroid Associated Ophthalmopathy · Thyroid Associated Orbitopathy

Abroad (travel likely)RecruitingPHASE3

Malmö, Sweden

Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy

Thyroid Associated Ophthalmopathy

Abroad (travel likely)Recruiting

Hangzhou, China

Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy

Thyroid Associated Ophthalmopathy

Abroad (travel likely)Recruiting

Shanghai, China